RGL1

Across TCGA pan-cancer cohorts, RGL1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RGL1 data layer compared with 21 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RGL1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RGL1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where RGL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.896	0.406	.001	87	view →
PDAC	DFS	Tertile	II,III,IV	0.674	1.000	.002	37	view →
UCEC	DFS	Median	II,III,IV	0.201	0.742	.024	12	view →
LUAD	DFS	Median	All	0.752	0.492	.004	11	view →
GBM	DFS	Quartile	All	0.474	0.216	.003	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RGL1–CCRCC (DFS)

Open the CCRCC breakdown →